Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe

Table 4 Arithmetic mean live Ixodes ricinus counts for dogs dosed once orally with sarolaner + moxidectin + pyrantel and efficacy relative to placebo (Studies 4 and 5)

Tick strain origin^a	Count day	Placebo		1.2 mg/kg sarolaner + 24 µg moxidectin + 5 mg/kg pyrantel			Test statistic (vs placebo)
Tick strain origin^a	Count day	Mean	Range	Mean^b	Range	% Efficacy	Test statistic (vs placebo)
Slovakia, Germany and Ireland (Slovakia and Ireland)	2	15.4	9–20	0	0	100	t_(15.3) = 31.2 P < 0.0001
	7	14.3	12–18	0	0	100	t_(11.8) = 57.63 P < 0.0001
	14	14.0	10–16	0	0	100	t_(9.4) = 46.63 P < 0.0001
	21	16.1	13–20	0	0	100	t_(13.8) = 54.8 P < 0.0001
	28	14.9	13–20	0	0	100	t_(12.8) = 55.78 P < 0.0001
	35	15.4	10–20	0	0	100	t₍₁₄₎ = 27.15 P < 0.0001
Germany (Germany)	2	15.9	3–25	0	0	100	t_(14.3) = 13.25 P < 0.0001
	7	14.0	9–18	0	0	100	t_(14.2) = 38.09 P < 0.0001
	14	16.4	10–22	0	0	100	t_(14.2) = 35.42 P < 0.0001
	21	15.6	10–21	0	0	100	t_(14.2) = 32.02 P < 0.0001
	28	17.6	11–23	0	0	100	t_(13.8) = 32.93 P < 0.0001
	35	18.0	15–20	0.5	0–4	97.2	t_(14.1) = 13.34 P < 0.0001

^aCountries from which ticks were originally isolated to establish colony (countries of origin for ticks subsequently used to enrich colony the last time 1 and 2 years before study conduct, respectively)
^bMean live tick count significantly lower than placebo (Study 4: 17.16 ≤ t_df ≤ 63.54, 9.4 ≤ df ≤ 15.3; Study 5: 13.25 ≤ t_df ≤ 38.09, 13.8 ≤ df ≤ 14.3, P < 0.0001) at all time-points

ISSN: 1756-3305